Global Myelofibrosis MF Analysis 2025, Forecast To 2034
26 Mar, 2025
What Is The Current and Historic Market Size Analysis Of The Myelofibrosis MF Market?
The myelofibrosis mf market has seen considerable growth due to a variety of factors.
• The market size of myelofibrosis (MF) has been experiencing consistent growth over the recent years. The market, estimated to be worth $1.50 billion in 2024, is projected to reach $1.55 billion by 2025, with a compound annual growth rate (CAGR) of 3.5%.
Factors such as the growing incidence of myeloproliferative neoplasms, heightened awareness and advancement in early diagnosis, increased usage of JAK inhibitors, enhanced accessibility to bone marrow transplants, and approval of more new therapies by regulatory bodies have all contributed to the growth observed in the historical period.
What Are The Predictions for The Myelofibrosis MF Market in the Coming Years?
The myelofibrosis mf market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for myelofibrosis (MF) will witness consistent growth in the coming years, expanding to $1.76 billion in 2029, with a compound annual growth rate (CAGR) of 3.2%.
Factors fueling growth over this forecast period include a surge in demand for tailored treatment methodologies, an increment in clinical experiments for gene and cell therapies, greater usage of combination therapies, increased healthcare coverage for uncommon diseases, and enhanced investment in the area of hematology care. Key trends being seen in the forecast period encompass advances in gene-editing technology; innovations in drugs that target myelofibrosis; the development of next-generation Janus kinase (JAK) inhibitors; a rising fascination with immunotherapy as a treatment for myelofibrosis; and the expanding application of artificial intelligence in the area of drug discovery.
Which Drivers Are Accelerating Growth In The Myelofibrosis MF Market?
The increase in targeted therapy requirement is anticipated to boost the development of the myelofibrosis (MF) market. Targeted therapy is a medical strategy that personalizes treatment and health decisions based on the unique genetic make-up, environmental conditions and lifestyle habits of each patient. The surge in the need for such therapies can be attributed to progress in genomics, biotechnology, and data analysis, which facilitate more accurate, effective and personalized therapies. Myelofibrosis (MF) plays a vital role in the creation of targeted therapies by determining essential molecular pathways, such as JAK-STAT signaling. This is used in conceptualizing precision treatments like JAK inhibitors (Ruxolitinib, Fedratinib, and Pacritinib) to control signs and slow down the disease's advancement. For example, in April 2024, the American Society of Gene & Cell Therapy, a US-government institution, reportedly said that the count of therapies at all clinical pipeline development stages has seen a rise, with Phase I therapies showing a remarkable surge of 11%—the most significant growth since Q4 2022. Hence, the rising need for targeted therapies is fueling the expansion of the myelofibrosis (MF) market.
What Are The Core Segments Of The Global Myelofibrosis MF Market?
The myelofibrosis (MF) market covered in this report is segmented –
1) By Drug Type: Jak Inhibitor, Immunomodulators, Hydroxyurea, Other Drug Types
2) By Treatment Type: Chemotherapy, Targeted Therapy, Other Treatment Types
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Jak Inhibitor: Ruxolitinib, Fedratinib, Momelotinib, Itacitinib
2) By Immunomodulators: Thalidomide, Lenalidomide, Pomalidomide
3) By Hydroxyurea: Oral Hydroxyurea, Injectable Hydroxyurea
4) By Other Drug Types: Erythropoiesis-Stimulating Agents (ESAs), Danazol, Monoclonal Antibodies, Chemotherapy Agents
What Trends Are Reshaping The Future Of The Myelofibrosis MF Market?
Leading firms in the myelofibrosis (MF) market are prioritizing the growth of targeted therapies like JAK1/JAK2 and ACVR1 inhibitors to improve treatment effectiveness, manage disease advancement, and enhance patient results in myelofibrosis. JAK1/JAK2 inhibitors reduce inflammation and abnormal blood cell production in myelofibrosis by targeting the Janus kinase pathway, while ACVR1 inhibitors control bone marrow fibrosis and disease progression by blocking activin receptor-like kinase 2 (ALK2). In September 2023, for example, UK pharmaceutical corporation, GSK plc, achieved US Food and Drug Administration (FDA) authorization for Ojjaara (momelotinib), a medication for intermediate- or high-risk myelofibrosis. Its dual action on JAK1/JAK2 and ACVR1 targets, in turn, manages inflammatory pathways and boosts hemoglobin levels, decreasing the need for transfusions. This authorization not only broadens therapy choices but also establishes a fresh benchmark in MF management for anemia-afflicted patients, a significant unresolved need in the disease scenario.
Who Are the Key Players In The Myelofibrosis MF Market?
Major companies operating in the myelofibrosis (MF) market are:
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• Merck & Co. Inc.
• AbbVie Inc.
• Sanofi S.A.
• Bristol-Myers Squibb Company
• Novartis AG
• GlaxoSmithKline plc
• Eli Lilly and Company
• Gilead Sciences Inc.
• A. Menarini Industrie Farmaceutiche Riunite S.r.l.. Incyte Corporation
• Sobi Inc.
• MorphoSys AG
• CTI BioPharma Corp.
• Suzhou Zelgen Biopharmaceutical Co. Ltd.
• NS Pharma Inc.
• Impact Biomedicines Inc.
• Kartos Therapeutics Inc.
• Geron Corporation
What Are The Regional Insights Into The Myelofibrosis MF Market?
North America was the largest region in the myelofibrosis (MF) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the myelofibrosis (MF) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.